Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma

Authors:

Abstract
9011 Background: Anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma. To improve tolerability and potentially efficacy of this combination we combined liposomal daunorubicin (L-Dauno) with high dose continuous infusion ifosfamide. Methods: In a single-arm phase II study 40 patients were enrolled with a median age of 57 years (19 to 78 years). Treatment regimen was L-Dauno 100 mg/m2 and ifosfamide 5 g/m2 over 24 h every 4 weeks with G-CSF support. Initially, 5 patients were included after failure of a doxorubicin/ifosfamide regimen, but none of these responded. Subsequently, 35 patients were treated first line. Results: A total of 115 cycles (range 1 to 7) were given. Toxicity was tolerable with 5 episodes (4,8 % of cycles) of ifosfamide related CNS toxicity grade II and 9 episodes (8,6 % of cycles) of neutropenic fever. Treatment had to be terminated due to a pseudo-allergic reaction to L-Dauno in one patient. One patient had ifosfamide related acute renal failure and was further treated with L-Dauno alone. No other non-hematological toxicity exceeding grade II was observed. Eleven (31,4 %) out of 35 patients without pretreatment achieved a PR, all after 2 treatment cycles, 6 patients (17,1 %) had stable disease and 12 patients (34,3 %) progressed; 6 patient were not evaluable (2 treatment unrelated early deaths, 2 lost to follow up, 1 adjuvant treatment, 1 to early to evaluate). Median time to progression was 10 months, median overall survival 16 months. PR with respect to histology was: 4/7 PNET, 1/6 leiomyosarcoma, 2/4 liposarcoma, 1/2 synovial sarcoma, 1/3 pleomorphic sarcoma, 1/1 malignant histiocytoma and 1/2 carcinosarcoma. Four of the responding patients received a consolidating high-dose-chemotherapy with subsequent stem cell support. Conclusions: IDx is a well tolerated and highly active chemotherapy regimen for first line treatment of soft tissue sarcoma, even in elderly patients. Randomized studies with this regimen are warranted. No significant financial relationships to disclose.